Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07286006 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 105 → 131 locations
    • Eligibility criteria expanded, about 3 words
  2. Trial sites expanded: 93 → 105 locationsv8
  3. Trial sites expanded: 90 → 93 locationsv7
  4. Study sites: 89 to 90v6
  5. 2 versions Re-verified since Apr 24, 2026, no change to tracked fieldsv4-v5
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 90 to 89v3
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Study sites: 0 to 90
    • Start date changed from estimate of Feb 2026 to Jan 26, 2026
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
Trial Details
NCT Number NCT07286006
Lead Sponsor Immunovant Sciences GmbH
Conditions
(from sponsor)		 Graves' Disease
Related terms Graves Disease
Enrollment 372 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov